Genscript Biotech Corporation (Genscript) issued a voluntary announcement on 10 November 2026 to inform shareholders that its associate, Legend Biotech Corporation (Legend), has released financial results for the quarter ended 30 September 2026.
Legend, whose American Depositary Shares trade on the Nasdaq Global Select Market, submitted a Form 6-K to the U.S. Securities and Exchange Commission on the same day. The filing details Legend’s third-quarter 2026 financial performance and recent business developments.
Genscript emphasized that the disclosed figures relate solely to Legend and do not reflect Genscript’s own financial results. The Board advised shareholders and prospective investors to consider the inherent investment risks and to exercise caution when dealing in Genscript’s securities.
The complete Form 6-K is available on the SEC website at: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000026/0001801198-26-000026-index.html.
Comments